No effect of exogenous melatonin on development of cryopreserved metaphase II oocytes in mouse

Table 2 Parthenogenetic development of vitrified-warmed mouse MII oocytes after melatonin treatment

Group (melatonin treatment)	Total No. of oocytes examined	No. of oocytes survived	No. of oocytes developed to
Group (melatonin treatment)	Total No. of oocytes examined	No. of oocytes survived	2-cell (%)^a	Blastocyst (%)^a
0 mol/L	60	51	41(80.39 ± 5.19)^b	27(52.94 ± 5.88)^b
10⁻⁹ mol/L	120	97	73(81.31 ± 3.60)^b	47(55.04 ± 3.80)^b
10⁻⁷ mol/L	100	88	67(79.95 ± 4.05)^b	40(42.36 ± 6.08)^b
10⁻⁵ mol/L	100	84	57(74.24 ± 6.73)^b	41(54.58 ± 6.11)^b
10⁻³ mol/L	100	88	50(54.84 ± 7.92)^c	29(47.22 ± 2.78)^b

1,^.a Number of 2-cell or blastocyst/Number of oocytes survived
2, Percentage data are presented as mean ± SEM from at least 3 replicates b and c, denote significant differences (P < 0.05)
3, Melatonin treatment: the vitrified-warmed mouse MII oocytes were cultured for 1 h in M₂ medium with different concentrations (0, 10⁻⁹, 10⁻⁷, 10⁻⁵, 10⁻³mol/L) of melatonin, respectively, then they were used for parthenogenetic activation

ISSN: 2049-1891